On Sep 7, 2021 Adaptimmune closed a Post-IPO Equity round and raised $150,000,000 from Genentech, featuring lead investors Genentech.
About the company: Adaptimmune is located at United Kingdom, Europe.
“Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients”
Company website: http://www.adaptimmune.com